(R)-Ethyl 2-(pyrrolidin-2-yl)acetate | 107870-33-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (R)-Ethyl 2-(pyrrolidin-2-yl)acetate
• 英文别名: ethyl 2-[(2R)-pyrrolidin-2-yl]acetate
• CAS: 107870-33-7
• 化学式: C₈H₁₅NO₂
• 分子量: 157.213
• InChiKey: MYUVDBULNNBWOG-SSDOTTSWSA-N

物化性质

• 沸点：
  210.9±13.0 °C(Predicted)
• 密度：
  0.989±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (R)-Ethyl 2-(pyrrolidin-2-yl)acetate 在 lithium aluminium tetrahydride 、 乙酸酐 作用下， 生成 (2R)-1-甲基-2-吡咯烷乙醇
  参考文献：
  名称：

  Asymmetric Synthesis of 1-Methyl-2-(2-hydroxyethyl)pyrrolidine

  摘要：

  DOI：

  10.3987/r-1986-07-1825
• 作为产物：
  描述：

  ethyl 2-[(2R)-1-[(1S)-1-phenylethyl]pyrrolidin-2-yl]acetate 在 palladium dihydroxide 氢气 作用下， 以 乙醇 为溶剂， 以100%的产率得到(R)-Ethyl 2-(pyrrolidin-2-yl)acetate
  参考文献：
  名称：

  Asymmetric Synthesis of 1-Methyl-2-(2-hydroxyethyl)pyrrolidine

  摘要：

  DOI：

  10.3987/r-1986-07-1825

文献信息

• [EN] FUSED PYRROLEDICARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS<br/>[FR] PYRROLEDICARBOXAMIDES FUSIONNÉS ET LEUR UTILISATION EN TANT QUE PRODUITS PHARMACEUTIQUES
  申请人：SANOFI SA

  公开号：WO2013113860A1

  公开（公告）日：2013-08-08

  The present invention relates to fused pyrroledicarboxamides of the formula (I), in which R1 to R9, X, m and n are as defined in the claims. The compounds of the formula (I) are inhibitors of the acid-sensitive potassium channel TASK-1 and suitable for the treatment of TASK-1 channel-mediated diseases such as arrhythmias, in particular atrial arrhythmias like atrial fibrillation or atrial flutter, and respiratory disorders, in particular sleep-related respiratory disorders like sleep apnea, for example.

  本发明涉及公式（I）中的融合吡咯二羧酰胺，其中R1至R9、X、m和n如权利要求中所定义。公式（I）化合物是酸敏感钾通道TASK-1的抑制剂，适用于治疗TASK-1通道介导的疾病，如心律失常，特别是心房心律失常，如心房颤动或心房扑动，以及呼吸系统疾病，特别是与睡眠相关的呼吸系统疾病，如睡眠呼吸暂停症等。
• CARBOXYLIC ACID AMIDES, THE PREPARATION THEREOF, AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS
  申请人：Gillard James

  公开号：US20080132496A1

  公开（公告）日：2008-06-05

  Substituted carboxylic acid amides of general formula wherein A, B, and R 1 to R 5 are as defined herein, and the tautomers and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable properties, such as antithrombotic activity and factor Xa-inhibiting activity.

  通式为的取代羧酸酰胺，其中A、B和R1至R5的定义如本文所述，以及它们的互变异构体和盐，特别是与无机或有机酸或碱的生理上可接受的盐，具有有价值的性质，如抗血栓活性和Xa因子抑制活性。
• Carboxylic acid amides, the preparation thereof, and their use as pharmaceutical compositions
  申请人：Boehringer Ingelheim Pharma GmbH & Co., KG

  公开号：US07326791B2

  公开（公告）日：2008-02-05

  Substituted carboxylic acid amides of general formula wherein A, B, and R1 to R5 are as defined herein, and the tautomers and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable properties, such as antithrombotic activity and factor Xa-inhibiting activity.

  通式为其中A、B、R1至R5如定义的羧酸酰胺及其互变异构体和盐，特别是与无机或有机酸或碱的生理上可接受的盐，具有有价值的特性，如抗血栓活性和Xa因子抑制活性。
• Fused Pyrroledicarboxamides and Their Use as Pharmaceuticals
  申请人：SANOFI

  公开号：US20160159793A1

  公开（公告）日：2016-06-09

  The present invention relates in fused pyrroledicarboxamides of the formula (I), in which R1 to R9, X, m and n are as defined in claims. The compounds of the formula (I) are inhibitors of the acid-sensitive potassium channel TASK-1 and suitable for the treatment of TASK-1 channel-mediated diseases such as arrhythmias, in particular atrial arrhythmias like atrial fibrillation or atrial flutter, and respiratory disorders, in particular sleep-related respiratory disorders like sleep apnea, for example.

  本发明涉及式(I)的融合吡咯二酰胺，其中R1至R9、X、m和n如权利要求中所定义。公式(I)化合物是酸敏感钾通道TASK-1的抑制剂，适用于治疗TASK-1通道介导的疾病，如心律失常，特别是房颤或心房扑动，以及呼吸系统疾病，特别是睡眠相关呼吸障碍，如睡眠呼吸暂停等。
• NIKIFOROV T., HETEROCYCLES, 24,(1986) N 7, 1825-1829
  作者：NIKIFOROV T.

  DOI：——

  日期：——